Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté
7ans d'exercice (thèse 2019)·8 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
6
6 articles ont été cités au moins 6fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
149
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
19
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
4
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut polytechnique de Grenoble · Centre National de la Recherche Scientifique · Centre Hospitalier Universitaire de Grenoble
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Top 10 palliative care research priorities in France: a 3-step, mixed-methods protocol (AXEPRO study)
2025ArticleBMJ Open
Epidemiology of psychiatric disorders following cytoreductive surgeries plus hyperthermic intraperitoneal chemotherapy: a prospective cohort analysis
2023ArticleScientific Reports
Validation of a French version of the Breakthrough Pain Assessment Tool in cancer patients: Factorial structure, reliability and responsiveness
2023ArticlePLoS ONE
Détresse financière en phase palliative chez les patients atteints de cancer : vers une approche structurée des coûts de la fin de vie
2019Thèse
Inequalities in Financial Distress, Symptoms, and Quality of Life Among Patients with Advanced Cancer in France and the U.S.
2019ArticleOncologist
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL NORD - CHU38
BD DE LA CHANTOURNE, 38700 LA TRONCHE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The oncologist · 2019
Abstract Background Financial distress (FD) is common among patients with advanced cancer. Our purpose was to compare the frequency and intensity of FD and its associations with symptom distress and quality of life (QOL) in these patients in France and the U.S. Materials and Methods In this secondary analysis of two cross-sectional studies, we assessed data on 292 patients who received cancer care at a public hospital or a comprehensive cancer center in France (143 patients) or the U.S. (149 patients). Outpatients and hospitalized patients over 18 years of age with advanced lung or breast or colorectal or prostate cancer were included. Diagnosed cognitive disorder was considered a noninclusion criterion. Advanced cancer included relapse or metastasis or locally advanced cancer or at least a second-line chemotherapy regimen. Patients self-rated FD and assessed symptoms, psychosocial distress, and QOL on validated questionnaires. Results The average patient age was 59 years, and 144 (49%) were female. FD and high intensity were reported more frequently in U.S. patients than in French (respectively 129 [88%] vs. 74 [52%], p < .001; 100 [98%] vs. 48 [34%], p < .001,). QOL was rated higher by the U.S. patients than by the French (69 [SD, 18] vs. 63 [SD, 18], p = .003). French patients had more psychological symptoms such as anxiety (8 [SD, 4] vs. 6 [SD, 5], p = .008). Associations were found between FD and U.S. residence, FD and single status (0.907, p = .023), and FD and metastasis (1.538, p = .036). In contrast, negative associations were found between FD and older age (−0.052, p = .003) and FD and France residence (−3.376, p = .001). Conclusion Regardless of health care system, FD is frequent in patients with advanced cancer. U.S. patients were more likely to have FD than French patients but reported better QOL. Further research should focus on factors contributing to FD and opportunities for remediation.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
Cancer medicine · 2022
AbstractBackgroundPrognostic scales exist to estimate patient survival in advanced cancer. However, there are no studies evaluating their use and practice. The objective of this study was to evaluate in a nationwide study the proportion of oncologists and palliative care physicians who had knowledge of these scales.MethodsA descriptive, national, cross‐sectional study was conducted via an online questionnaire to oncologists and palliative care physicians across France.ResultsPalliative care physicians had better knowledge of the scales than oncologists (42.3% (n = 74) vs. 27.8% (n = 33), p = 0.015). The Palliative Performance Status (PPS) and Pronopall Scale were the best‐known (51.4% (n = 55) and 65.4% (n = 70), respectively) and the most widely used (35% (n = 28) and 60% (n = 48), respectively). Improved training in the use of these scales was requested by 85.4% (n = 251) of participants, while 72.8% (n = 214) reported that they did not use them at all. Limited training and lack of consensus on which scale to use were cited as the main obstacles to use.ConclusionThis is the first national study on the use of prognostic scales in advanced cancer. Our findings highlight a need to improve training in these scales and to reach a consensus on scale selection.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cancer medicine · 2024 · Journal Article
Stephanopoli JP, Bouazzi L, Guerbaz-Sommi M, Graesslin O, et al.
Scientific reports · 2023 · Journal Article
Economos G, Kepenekian V, Barbaret C, Villeneuve L, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · Journal Article
Auclair J, Sanchez S, Chrusciel J, Hannetel L, et al.
Cancer medicine · 2022 · Journal Article
Dantigny R, Ecarnot F, Economos G, Perceau-Chambard E, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · Journal Article
Chechirlian K, Messin M, Dantigny RH, Economos G, et al.
Sexual medicine reviews · 2024 · Journal Article
Donz R, Russia B, Barbaret C, Braybrook D, et al.
The oncologist · 2019 · Journal Article
Barbaret C, Delgado-Guay MO, Sanchez S, Brosse C, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · Journal Article
Chechirlian K, Messin M, Dantigny RH, Economos G, et al.